Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. (2021)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)32341-2
PubMed Identifier: 33485455
Publication URI: http://europepmc.org/abstract/MED/33485455
Type: Journal Article/Review
Volume: 397
Parent Publication: Lancet (London, England)
Issue: 10271
ISSN: 0140-6736